Oral Dosing

Oral Dosing

ORAL DOSING FOR INLYTA® (axitinib)

Reference
  1. Rugo HS, Herbst RS, Liu G, et al. Phase 1 trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474-5483.